LIANYPNKHealthcare

LianBio

+28.4% · 90d

$0.12

+0.00 (+0.00%)

News

No News Yet

Press releases and SEC filings for LIANY will appear here as they are published.

Check back later for updates

Key Data

Market Cap$13.3M

Open$0.12

Prev Close$0.12

Day Range$0.12 – $0.12

52W Range$0.03 – $0.44

Volume501

P/E (TTM)—

EPS$-1.53

Dividend Yield—

Beta0.10

About

LianBio, operates as a biotechnology company in China and other Asian countries. It offers medicines for cardiovascular, oncology, ophthalmology, and inflammatory disease indications. The company develops mavacamten for the treatment of obstructive hypertrophic cardiomyopathy, which is in Phase 3 EXPLORER-CN trial; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease, which is in Phase 3 LIBRA trial; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of FGFR2 gene amplification; and BBP-398 for solid tumors. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.

Healthcare · Biotechnology

163 employees

www.lianbio.com

Top Institutional Holders

As of 2025-12-31 · prior 2025-06-30

FNY Investment Advisers, LLC$1

14,000 sh0.0%

See all holders →